Syros to Participate in Upcoming Virtual Investor Conferences in March
February 28 2022 - 7:30AM
Business Wire
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development
of medicines that control the expression of genes, today announced
that its Chief Executive Officer, Nancy Simonian, M.D., will
participate in a panel discussion and present a corporate overview
at two upcoming virtual investor conferences in March. Management
will also be available for one-on-one meetings. Details are as
follows:
Cowen 42nd Annual Healthcare Conference Date: Monday,
March 7 Panel Title: Novel Oncology Targets Panel Time: 12:50 p.m.
ET
Oppenheimer 32nd Annual Healthcare Conference Date:
Wednesday, March 16 Presentation Time: 3:20 p.m. ET
To access the webcasts and subsequent archived recording of each
event, please visit the Investors & Media section of the Syros
website at www.syros.com. An archived replay of each webcast will
be available for approximately 30 days following each
presentation.
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the
expression of genes. Based on its unique ability to elucidate
regulatory regions of the genome, Syros aims to develop medicines
that provide a profound benefit for patients with diseases that
have eluded other genomics-based approaches. Syros is advancing a
robust clinical-stage pipeline, including: tamibarotene, a
first-in-class oral selective RARα agonist in RARA-positive
patients with higher-risk myelodysplastic syndrome and acute
myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in
patients with acute promyelocytic leukemia; and SY-5609, a highly
selective and potent oral CDK7 inhibitor in patients with select
solid tumors and blood cancers. Syros also has multiple preclinical
and discovery programs in oncology and monogenic diseases. For more
information, visit www.syros.com and follow us on Twitter
(@SyrosPharma) and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220228005020/en/
Media Contact: Courtney Solberg Syros Pharmaceuticals
917-698-9253 csolberg@syros.com
Investor Contact: Hannah Deresiewicz Stern Investor
Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Apr 2023 to Apr 2024